Misoprostol to Improve Cervical Cancer Screening in Africa
Official title: Misoprostol to Optimize Prevention of Cancer of the Cervix: A Randomized Trial (MISOPCx Project)
Funded at University of Alabama at Birmingham · NIH-11527008 · Data updated 2026-11-12
A study tests whether a cheap, single-dose misoprostol helps more women in Africa see the cervix clearly during screening, potentially catching precancerous changes earlier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | March 15, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2026 |
| Award (this year) | $115,366 |
| NIH project number | 3R01CA279021-03S1 |
| Project ID | NIH-11527008 on NIH RePORTER |
Who could benefit from this research
✓Could help
Women in LMICs undergoing VIA cervical cancer screening, particularly those with type 3 transformation zone visualization challenges.
✕Less likely to help
Women for whom misoprostol is contraindicated or who do not experience improved TZ visualization in the trial.
What this research studies
This project focuses on improving cervical cancer screening in LMICs, where VIA is common and HPV testing is not universally available. It will test different durations of misoprostol to see if it can improve visualization of the transformation zone during VIA, potentially reducing missed lesions. The team from the University of Alabama at Birmingham will partner with sites in Africa to assess feasibility, safety, and acceptance of the intervention in real-world screening settings. The study design is randomized, aiming to provide robust evidence about whether misoprostol can enhance screening accuracy and outcomes. If successful, the approach could be scaled to lower the burden of cervical cancer in high-risk regions.
Why it matters
Potential benefit: If effective, the misoprostol approach could improve detection of precancer or early cancer, leading to earlier treatment and fewer deaths.
How similar studies have gone: Prior small trials suggested potential benefits, but larger, definitive evidence is still needed.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Huh, Warner King — University of Alabama at Birmingham
- Study coordinator: Huh, Warner King
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.